Naturhouse Health S.A. (0R9G) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Naturhouse Health S.A. €2.11, price €2.20, upside -4.1%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Naturhouse Health S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range €0.9292 – €2.62 · fair‑value band €1.61 – €2.60 · the €2.20 price screens above the €2.11 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Follow Naturhouse Health in your weekly email
Every Wednesday you see whether Naturhouse Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Naturhouse Health, S.A. operates in the nutrition and dietetics industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and food and drinks, such as diet products for breakfast, snacks, and meal substitutes.
Show more
Naturhouse Health, S.A. operates in the nutrition and dietetics industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and food and drinks, such as diet products for breakfast, snacks, and meal substitutes. It also offers cosmetics and body care products, including beauty products related to skincare during the slimming process comprising cellulite, firming products, etc.; and anti-ageing products. In addition, the company engages in the production, preparation, and marketing of dietary products; and marketing of medicinal herbs and natural cosmetics. It sells its products through directly operated stores and franchised Naturhouse centers. The company was formerly known as Housediet, S.L.U. and changed its name to Naturhouse Health, S.A. Naturhouse Health, S.A. was incorporated in 1991 and is based in Madrid, Spain. Naturhouse Health, S.A. is a subsidiary of Kiluva S.A.
Stock analysis
Naturhouse Health S.A. (0R9G) currently trades at €2.20, while our model-based Fair Value estimate is €2.11, so the stock looks roughly fairly valued today (gap 4.3%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €2.48 per share, and 8 of the 23 models we run sit above the €2.20 price.
Bear case: the Asset-Based group reads lowest at €0.2900, and 15 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: €1.61 (bear) to €2.60 (bull), the price of €2.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Industrials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Naturhouse Health S.A. reported revenue of €55.1M in FY2020 versus €97.8M in FY2016, a compound −13.4%/yr. Reported net income was €9.4M in FY2020, compounding −19.7%/yr from FY2016.
Key figures
Market cap €144M · P/E ratio 0.1 · P/S ratio 0.02 · EPS (TTM) €0.2200 · Net margin 17.0% · Return on equity 40.8% · Return on assets (EBIT) 58.5% · Operating margin 23.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (medium confidence).
What moves the price
The share trades about 16% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −40% fair-value upside, at −4%, 0R9G screens cheaper than that median.
Fair Value models
Bear €1.61Fair Value €2.11Bull €2.60
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−32.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.5%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.1% (2016) → 24.0% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Commercial Services & Supplies” was too small, so the broader sector is used.)Industrials · 5328 stocks
Beats the sector median on 7/9 measures
Overall it ranks above its sector peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside−4.1% · Above median
Profitability
Return on equity (TTM)40.8% · Top 25%
Return on assets21.8% · Top 25%
Net margin (TTM)21.2% · Top 25%
Operating margin (TTM)23.8% · Top 25%
Growth and dividend
Revenue growth−0.8% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Industrials median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Naturhouse Health S.A. Fair Value". https://www.fairvalue-calculator.com/stock/0R9G
Frequently asked questions
Is Naturhouse Health S.A. (0R9G) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of €2.11 versus a price of €2.20, about −4% upside (fairly valued).
What is the fair value of 0R9G?
Our model-based fair value for Naturhouse Health S.A. is €2.11 (as of Oct 2, 2026), built from audited fundamentals. The current price: €2.20.
What is the quality score of 0R9G?
Naturhouse Health S.A. has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Naturhouse Health S.A. (0R9G)?
Our model-based price target is the fair value of €2.11 (as of Oct 2, 2026) from 23 valuation models. Cautious scenario €1.61, optimistic scenario €2.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Naturhouse Health S.A. stock forecast for 2026?
Our models put fair value at €2.11, about −4% upside versus a price of €2.20 (fairly valued). Cautious scenario €1.61, optimistic scenario €2.60. The calculation is refreshed regularly with new filings.
What is the revenue of Naturhouse Health S.A. (0R9G)?
Naturhouse Health S.A. reported trailing-twelve-month revenue of about €47.6M (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Naturhouse Health S.A. (0R9G)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Naturhouse Health S.A. it is €2.11 per share (as of Oct 2, 2026), against a price of €2.20. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Naturhouse Health S.A. stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 0R9G trades above its calculated fair value: price €2.20, fair value €2.11, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0R9G?
No. The price is what the market pays today (€2.20); the fair value is what the company's own numbers justify (€2.11). For Naturhouse Health S.A. the two are €0.0900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Naturhouse Health S.A. worth?
The market values Naturhouse Health S.A. at about €144M (market capitalisation, as of Oct 2, 2026). Per share that is €2.20; our models calculate a fair value of €2.11 per share.
What do the bullish and bearish scenarios say about 0R9G?
Our models span a range for Naturhouse Health S.A.: cautious scenario €1.61, base €2.11, optimistic €2.60 per share (as of Oct 2, 2026, price €2.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0R9G?
Naturhouse Health S.A. trades at a price-to-earnings ratio of 0.1 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €2.11 is built from several models across several years.
How solid is the balance sheet of Naturhouse Health S.A. (0R9G)?
Balance-sheet figures for Naturhouse Health S.A. (as of Oct 2, 2026): return on equity 40.8%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is 0R9G from its 52-week high?
Naturhouse Health S.A. trades at €2.20, about 16% below its 52-week high of €2.62 and 17% above the low of €1.88 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €2.11 is for.
Which stocks are comparable to Naturhouse Health S.A.?
From the same area (Industrials) we also value Contemporary Amperex Technology Co, Delta Electronics (Thailand) Public Company, Larsen & Toubro Limited, Samsung C&T Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Naturhouse Health S.A. stock attractive at the current price?
The data as of Oct 2, 2026: price €2.20, calculated fair value €2.11 (−4%), Quality Score 75/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0R9G calculated?
We run Naturhouse Health S.A. through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €2.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Naturhouse Health S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Naturhouse Health S.A. (0R9G)?
The closing price on Oct 2, 2026 was €2.20. Our model-based fair value is €2.11, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Naturhouse Health S.A. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Naturhouse Health S.A.
How large is the market capitalisation of Naturhouse Health S.A. (0R9G)?
The market capitalisation of Naturhouse Health S.A. is €144M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Naturhouse Health S.A. (0R9G)?
The price-to-sales ratio of Naturhouse Health S.A. is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Naturhouse Health S.A. (0R9G)?
Earnings per share at Naturhouse Health S.A. are €0.2200 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Naturhouse Health S.A. (0R9G)?
The net margin of Naturhouse Health S.A. is 17.0% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Naturhouse Health S.A. (0R9G)?
The return on equity (ROE) of Naturhouse Health S.A. is 40.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Naturhouse Health S.A. (0R9G)?
On an EBIT basis the return on assets of Naturhouse Health S.A. is 58.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Naturhouse Health S.A. (0R9G)?
The operating margin of Naturhouse Health S.A. is 23.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Naturhouse Health S.A. (0R9G)?
Revenue at Naturhouse Health S.A. is growing −0.8% versus a year earlier (3y avg −16.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Naturhouse Health S.A. (0R9G)?
Earnings per share at Naturhouse Health S.A. are growing +8.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Naturhouse Health S.A. in the live analysis
One click puts Naturhouse Health S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
